Biosimilar medicines: Challenges and opportunities for the healthcare system in Greece
Published
Biosimilar medicines have now become a central topic of discussion in the European pharmaceutical market. These are medicines that are highly similar to already approved reference biological products and offer a reliable alternative for the treatment of serious diseases.
The European agenda places great emphasis on the use of these medicines, as their circulation contributes significantly to reducing pharmaceutical expenditure. For Greece, the integration of biosimilars into daily clinical practice represents a significant challenge, but also an opportunity to save resources within the National Health System.
Experts point out that proper information for doctors and patients is crucial for the success of this endeavor. Despite the high quality and safety provided by biosimilars, there is often hesitation in replacing reference products, a fact that requires targeted actions from the state.
The goal for our country is to create a stable framework that will encourage the use of biosimilars without compromising the quality of patient care. With the right strategy, Greece can align itself with European practices, while simultaneously ensuring the sustainability of the healthcare system for the coming years.
Sources: Healthpharma
More Greece news
- The electric Renault 5 gains greater range and arrives in Greece with a special Roland-Garros edition
- Greece to contribute €120 million to European fund for high-tech companies
- Decline in technology and artificial intelligence stocks: How exposed are Greek companies?
- Meeting of Fidan and Güler on the cable across three capitals
- Interview Poll: New Democracy First with 29.4%, Ten Parties in Parliament
- Greece-Cyprus Cable: What Hatzidakis Said About France's License
- Conference on Access to Healthcare: Stelios Kymbouropoulos on the Today Press panel
- Georgia Parasxou at the Health Access Greece conference